• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr David Brumley Discusses Concerns With Telemedicine Overutilization

Video

There may be some reluctance to reimburse telemedicine because there is a feeling that telemedicine costs might be added to overall cost, rather than be substituted, David Brumley, MD, MBA, senior medical director at Tufts Health Plan, explained at the 4th Annual Patient-Centered Diabetes Care Meeting, held April 7-8 in Teaneck, NJ.

There may be some reluctance to reimburse telemedicine because there is a feeling that telemedicine costs might be added to overall cost, rather than be substituted, David Brumley, MD, MBA, senior medical director at Tufts Health Plan, explained at the 4th Annual Patient-Centered Diabetes Care Meeting, held April 7-8 in Teaneck, NJ

Transcript (slightly modified)

Why do you think there has been a reluctance to dive into the telemedicine reimbursement?

Well, part of the concern around telemedicine, even though it has promise, is the concern that it might be additive and not substituted. So, for example, instead of having 3-4 office visits per year, and having 2 office visits and a few telemedicine, we’re concerned that you’ll still have 4 office visits plus the telemedicine. So we just want to make sure that, however it’s structured, that people are getting the value out of that, but not adding costs to the system.

What ways are there to control overutilization of telemedicine?

The way to control that is we’re developing and working on some of those ideas. Some of them would be requirements around what types of visits are reimbursable, some of the requirements around what’s the content. So for office visits, for example, there are criteria around proper coding and that contains certain elements that could potentially be one approach. We also think about adding copays and patient costs to control the unnecessary utilization.

Related Videos
Phaedra Corso, PhD, associate vice president for research at Indiana University
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Screenshot of Angela Jia, MD, PhD, during a video interview
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Alexander Kutikov, MD, during a video interview
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Screenshot of Joshua Meeks, MD, PhD, during a video interview
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.